<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RITODRINE HYDROCHLORIDE</span><br/>(ri'toe-dreen)<br/><span class="topboxtradename">Yutopar<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic agonist</span><br/><b>Prototype: </b>Isoproterenol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL, 15 mg/mL, 0.3 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Preferentially stimulates beta<sub>2</sub>-receptors in uterine smooth muscle, reducing intensity and frequency of uterine contractions and lengthening gestation period.
         (Actions may be eliminated by beta-adrenergic antagonists.) Transitory cardiovascular effects include increased cardiac output,
         increased maternal and fetal heart rates, and widening of maternal pulse pressure (beta<sub>1</sub> stimulation).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Beta<sub>2</sub>- adrenergic agonist clinically effective in preventing or delaying preterm labor (tocolytic effect). Uterine contractions
         will decrease in frequency and intensity during treatment.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To manage premature labor in selected patients.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Mild to moderate preeclampsia or eclampsia, intrauterine infection, cervix dilated 4 cm or more (in a single pregnancy); pregnancy
         (category C); hypertension; diabetes mellitus; prior to 20th wk or after 36th wk of pregnancy or if continuation of pregnancy
         would be hazardous to mother and fetus (e.g., antepartum hemorrhage, eclampsia, intrauterine fetal death, maternal cardiac
         disease, pulmonary hypertension, maternal hyperthyroidism, severe diabetes mellitus). Also hypovolemia, cardiac arrhythmias
         associated with tachycardia or digitalis intoxication, uncontrolled hypertension; thyrotoxicosis; bronchial asthma being treated
         with betamimetics or steroids; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant use of potassium-depleting diuretics, cardiac disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Premature Labor</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start 30 min before terminating infusion, 10 mg q2h for first 24 h, then 1020 mg q46h (max: 120 mg/d) <span class="rdroute">IV</span> 50100 mcg/min, may increase by 50 mcg/min q10min until uterine relaxation is achieved, may continue for up to 12 h after
               contractions have ceased<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p> 			Note: IV solution should be clear. Discard if cloudy or a precipitate is present. 		</p>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Add 150 mg ritodrine to 500 mL D5W or NS solution to yield 0.3 mg/mL (300 mcg/mL).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Begin at 50 mcg/min and increase by 50 mcg q10 min until desired response. Monitor IV infusion flow rate to prevent circulation
                  overload. Use a microdrip and infusion pump.  
               </p>
<ul>
<li>Place patient in left lateral recumbent position throughout the infusion period to reduce risk of hypotension.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store drug below 30° C (86° F). Do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> erythema, <span class="speceff-common">nervousness,</span> restlessness, anxiety, malaise, <span class="speceff-both">anaphylactic shock</span> <i>,</i> sweating, chills, drowsiness, weakness, myotonic and muscular dystrophies. <span class="typehead"> CNS:</span> Tremor, headache. <span class="typehead">CV:</span> <span class="speceff-common">Altered maternal and fetal heart rates and maternal BP</span> (dose related), <span class="speceff-common">palpitations,</span> arrhythmias, chest pain, pulmonary edema. <span class="typehead">Endocrine:</span> <span class="speceff-common">Temporary hyperglycemia.</span> <span class="typehead">GI:</span> Nausea, vomiting, epigastric distress, ileus, bloating, constipation, diarrhea. <span class="typehead">Urogenital:</span> Glycosuria. <span class="typehead">Respiratory:</span> Dyspnea, hyperventilation. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Ritodrine (IV route) may produce an increase in <span class="alt">serum</span> levels of <span class="alt">glucose,</span> <span class="alt">insulin,</span> and <span class="alt">free fatty acids,</span> and a decrease in <span class="alt">serum potassium.</span> It temporarily elevates results of <span class="alt">glucose tolerance test.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">corticosteroids</span> may precipitate pulmonary edema; <span class="classification">beta agonists</span> add to cardiovascular adverse effects; effects of both ritodrine and <span class="classification">beta blockers</span> antagonized. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 30% absorbed from GI tract. <span class="typehead">Peak:</span> 3060 min. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.72.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor continuously for pronounced dose-related adverse effects to maternal and fetal heart rates and maternal BP while infusion
            is running.
         </li>
<li>Be alert to S&amp;S of pulmonary edema (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any of the following: palpitations, chest pain, dizziness, respiratory distress, weakness, tremors, sweating
            or chills.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>